Melanotan I 10mg
Full-Body Melanogenesis Activator Without Central Stimulation
Melanotan I (afamelanotide) is a synthetic α-MSH analogue that activates MC1R receptors to stimulate melanin production throughout the skin. Unlike Melanotan II, it lacks centrally mediated effects, making it the preferred compound for pure photoprotection and tanning research.
Full-Body Melanogenesis Activator Without Central Stimulation
Melanotan I has been clinically studied for erythropoietic protoporphyria and UV photoprotection. It increases eumelanin synthesis via MC1R activation, producing uniform, long-lasting pigmentation without significant off-target receptor activity.
As one of the most studied compounds in the skin & anti-aging research space, Melanotan I has attracted sustained scientific interest across Skin pigmentation research, Photoprotection studies, Dermatology protocols. Peer-reviewed evidence indicates that fDA-approved analogue (afamelanotide) for EPP, which has positioned Melanotan I as a reference standard for researchers exploring skin pigmentation research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
Melanotan I Documented Benefits: 3 Documented Mechanisms
Uniform Pigmentation
Activates MC1R receptors across the skin for consistent, full-body melanin production.
Photoprotection
Increased eumelanin provides natural UV protection, studied for conditions like EPP.
Selective MC1R Activity
Minimal MC3R/MC4R activity compared to Melanotan II, reducing unwanted systemic effects.
How Melanotan I Works: Molecular Mechanism & Pathway
Synthetic α-MSH analogue binding MC1R receptors on melanocytes, triggering cAMP-mediated upregulation of tyrosinase and eumelanin synthesis.
The 3 primary research pathways identified for Melanotan I — Uniform Pigmentation, Photoprotection, Selective MC1R Activity — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that selective MC1R agonism with minimal central effects, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, Melanotan I's broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
Melanotan I is routinely studied alongside GHK-Cu and SNAP-8 in skin & anti-aging-focused compound panels. Researchers investigating skin pigmentation research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that long-lasting pigmentation vs natural UV tanning has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All Melanotan I research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- FDA-approved analogue (afamelanotide) for EPP
- Selective MC1R agonism with minimal central effects
- Long-lasting pigmentation vs natural UV tanning
Ideal For
- Skin pigmentation research
- Photoprotection studies
- Dermatology protocols
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on Melanotan I. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
FDA-approved analogue (afamelanotide) for EPP
Selective MC1R agonism with minimal central effects
Long-lasting pigmentation vs natural UV tanning
Third-Party Verified Every Batch
Each vial of Melanotan I is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
